Overview

Ensartinib in the Treatment of ALK Positive or MET Exon 14 Skipping Anvanced Solid Tumors Excluded Lung Cancer

Status:
NOT_YET_RECRUITING

Trial end date:
2027-12-30

Target enrollment:

Participant gender:

Summary

In lung cancer, ensartinib is effective in improving the prognosis of ALK positive /MET exon 14 skipping patients. However, patients with ALK positive /MET14 exon skipping non-lung cancer solid tumors have limited treatment options in the absence of standard treatment. We hope to bring a new effective and safe treatment option to these patients more efficiently.

Phase:

PHASE2

Details

Lead Sponsor:

Nanjing First Hospital, Nanjing Medical University

Treatments:

ensartinib